Gasiorek 2025 - Oral Amycretin First-in-Human Phase 1 Trial

The Lancet·July 1, 2025

A. Gasiorek

Summary

Oral amycretin, a unimolecular GLP-1 and amylin receptor agonist, appeared safe and tolerable and produced clinically meaningful body-weight reductions in adults with overweight or obesity.

Study Details

Study Design

First-in-human, phase 1, double-blind, randomized, placebo-controlled trial

Indication

Overweight or obesity

Intervention

Once-daily oral amycretin vs placebo

Species

Human

Risk of Bias Assessment

Early phase 1; small sample; Novo Nordisk-sponsored